aTyr Pharma, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against aTyr Pharma, Inc. (ATYR).

If you purchased or held aTyr Pharma securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About aTyr Pharma

aTyr Pharma is a biotechnology company headquartered in San Diego, California. They develop novel therapeutics based on tRNA synthetase biology. The company’s primary clinical-stage asset has been efzofitimod, a drug candidate aimed at treating pulmonary sarcoidosis, a rare lung disease.

The company has conducted multiple clinical trials, including a pivotal Phase 3 study known as EFZO-FIT. Over recent years, aTyr Pharma has allegedly suggested progress in its clinical programs and the potential impact of efzofitimod on patient care.

Potential Concerns Under Investigation

Lawyers are investigating whether aTyr Pharma made statements or omissions that could have misled investors regarding the prospects and risks associated with its lead drug candidate, efzofitimod. The focus of the investigation centers on the period from Nov. 9, 2023, through Sept. 15, 2025.

On Sept. 15, 2025, aTyr Pharma announced that the Phase 3 EFZO-FIT trial of efzofitimod failed its primary endpoint. The trial data revealed no statistically significant steroid-sparing benefit compared to placebo, with mean daily prednisone use of 2.79 mg for efzofitimod versus 3.52 mg for placebo.

This disclosure marked the first time investors learned that the drug did not perform as hoped. As a result, aTyr Pharma’s stock price fell 80% to $1.21 in pre-market trading, erasing nearly all of its market capitalization and resulting in aggregate losses estimated in the hundreds of millions of dollars.

Securities attorneys could examine whether prior statements by aTyr Pharma’s executives may have misrepresented the likelihood of trial success.

For example, on Nov. 9, 2023, announced third quarter results that highlighted a “positive DSMB review” for the Phase 3 study and “meaningful progress” in pulmonary sarcoidosis, projecting smooth completion of enrollment by the second quarter of 2024.

Later alleged statements, such as those from March 14, 2024, and August 13, 2024, continued to emphasize strong financial positioning and the transformative potential of efzofitimod. These communications were allegedly not accompanied by meaningful discussion of the risks or challenges inherent in the trial design or the potential for failure.

Legal professionals may review whether shareholders were adequately informed about the risks associated with the EFZO-FIT trial. The investigation might look into whether aTyr Pharma’s references to earlier clinical data, such as Phase 1b/2a results, were presented without proper context regarding their limitations.

These earlier studies were often cited to suggest efzofitimod’s effectiveness, but the later Phase 3 results contradicted those implications. Securities attorneys could also examine the impact of the company’s alleged statements on investor expectations and the resulting harm.

The sharp, single-day drop in stock price following the trial results suggests that the market was not prepared for such a negative outcome, and that prior communications or lack thereof may have contributed to inflated share prices.

Your Rights and Next Steps

Investors who purchased aTyr Pharma securities between Nov. 9, 2023, and Sept. 15, 2025, and suffered financial losses may have important legal rights. This is currently an investigation, not a filed lawsuit, but it may lead to a class action on behalf of affected investors.

Lawyers are ready to help investors understand their options. If the investigation uncovers evidence that aTyr Pharma may have made misleading statements or failed to disclose material risks, a class action lawsuit could be filed seeking to recover losses on behalf of all eligible investors.

Investors who held shares through the alleged corrective disclosure on Sept. 15, 2025 (the date the Phase 3 trial results were announced) may be eligible to participate in any future class action and seek compensation for their losses.

It is important for investors to act quickly, as securities investigations can be time-sensitive and may involve strict deadlines for joining a potential class action. Investors are encouraged to gather documentation of their purchases and sales of aTyr Pharma securities during the relevant period.

You May Be Entitled to Compensation

If you purchased or held aTyr Pharma securities and experienced financial losses following the company’s disclosures, you may be eligible to join this securities investigation and potentially recover compensation.

Securities investigations are time-sensitive, and acting promptly can help preserve your rights.

To learn more about your options and to participate in the investigation, complete the form below.